Boston Scientific continues to deliver robust growth, but valuation limits upside despite strong execution and leading positions in key medical device markets. BSX's growth drivers—Farapulse (PFA), ...

Boston Scientific (BSX) has quietly outperformed many medtech peers this year, and with the stock hovering near 96 dollars after a modest pullback, investors are asking whether this long term ...

Boston Scientific is recommended as a buy with a $109 target price, implying 14% upside, driven by robust demand and niche leadership. BSX outpaces market growth through focused M&A, strong execution ...

Boston Scientific (BSX) closed the most recent trading day at $97.79, moving +2.42% from the previous trading session. This change outpaced the S&P 500's 0.62% gain on the day. On the other hand, the ...

Boston Scientific (NYSE:BSX) has outperformed the market over the past 15 years by 6.72% on an annualized basis producing an average annual return of 18.55%. Currently, Boston Scientific has a market ...

Hardman Johnston Global Advisors, an investment management company, released its “Hardman Johnston Global Equity Strategy” investor letter for the third quarter of 2025. A copy of the letter can be ...

In the early 1960s, Mack Fulwyler joined the lab of Marvin Van Dilla at the Los Alamos National Laboratory as an engineer to study the effect of fallout radiation from nuclear weapons testing on ...

Foundational Concepts in Programming Industrial Robots. Before you can get a robot to do anything useful, you need to ...